VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb

Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, comments on the efficacy and toxicity profile of bispecific antibodies for multiple myeloma including teclistamab and elranatamab, discussing overall response rates (ORR), cytokine release syndrome (CRS) and infections. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter